Guizhou Bailing Group Pharmaceutical Co Ltd
SZSE:002424
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (2.4), the stock would be worth ¥5.71 (12% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.2 | ¥5.08 |
0%
|
| 3-Year Average | 2.4 | ¥5.71 |
+12%
|
| 5-Year Average | 2.5 | ¥5.76 |
+13%
|
| Industry Average | 2.4 | ¥5.62 |
+11%
|
| Country Average | 2.4 | ¥5.72 |
+13%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
G
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SZSE:002424
|
7.1B CNY | 2.2 | 3 197.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 30.3 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 6.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 5.9 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 5.2 | 15 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 7.2 | 20.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 6.1 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 1.7 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 6.3 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.4 |
| 70th Percentile | 3.9 |
| Max | 1 172 445.9 |
Other Multiples
Guizhou Bailing Group Pharmaceutical Co Ltd
Glance View
Guizhou Bailing Group Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicines. The company is headquartered in Anshun, Guizhou and currently employs 6,124 full-time employees. The company went IPO on 2010-06-03. The firm is also engaged in the provision of Chinese medicine materials. The firm is also engaged in the distribution of fertilizers and purified water, and the operation of medical institutions. The firm conducts its businesses mainly within domestic markets.
